Stock listing

OTC:OTLC Oncotelic Therapeutics Inc Stock

Follow Oncotelic Therapeutics Inc into a list and get an email when it puts out news.

Share price · OTC:OTLC

$0.012 USD -0.001 (-9.6%)

Close on Nov 20, 2026

Past year -87.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.012 – $0.012 USDNov 20, 2026
Volume
26,750 sharesNov 20, 2026
Market cap
$5.58M USDAt the close on Nov 20, 2026 · price × 457.5M shares outstanding
52-week range
$0.010 – $0.100 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$8,459 USDMedian day 285,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Oncotelic Therapeutics Inc logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:OTLC · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.012-0.001-9.6%$0.012$0.012$0.01226,750
$0.014+0.001+8.0%$0.013$0.014$0.01340,000
$0.013-0.001-6.7%$0.012$0.013$0.01265,500
$0.013+0.000+3.1%$0.012$0.013$0.01274,700
$0.0130.000-2.3%$0.012$0.013$0.012320,000
$0.013+0.003+33.0%$0.014$0.014$0.012274,225
$0.0100.0000.0%$0.020$0.020$0.010635,300
$0.010-0.010-50.0%$0.020$0.020$0.010285,200
$0.020+0.010+100.0%$0.010$0.020$0.010836,600
$0.0100.0000.0%$0.010$0.010$0.01092,300
$0.010-0.010-50.0%$0.020$0.020$0.010730,900
$0.0200.0000.0%$0.020$0.020$0.020684,200
$0.0200.0000.0%$0.020$0.020$0.020229,300
$0.0200.0000.0%$0.020$0.020$0.020728,800
$0.0200.0000.0%$0.020$0.030$0.020289,800
$0.0200.0000.0%$0.020$0.020$0.020390,600
$0.0200.0000.0%$0.020$0.020$0.0201,363,000
$0.0200.0000.0%$0.020$0.020$0.020699,600
$0.0200.0000.0%$0.020$0.020$0.020342,000
$0.0200.0000.0%$0.020$0.020$0.020254,100
$0.0200.0000.0%$0.020$0.020$0.02057,100
$0.0200.0000.0%$0.020$0.020$0.020238,300
$0.0200.0000.0%$0.020$0.020$0.020227,000
$0.0200.0000.0%$0.020$0.020$0.020204,600
$0.0200.0000.0%$0.020$0.020$0.020385,800
$0.0200.0000.0%$0.020$0.020$0.020504,500
$0.0200.0000.0%$0.020$0.020$0.020850,900
$0.0200.0000.0%$0.020$0.020$0.020438,400
$0.0200.0000.0%$0.020$0.020$0.020657,100
$0.0200.0000.0%$0.020$0.020$0.020480,100
$0.0200.0000.0%$0.020$0.030$0.020183,800
$0.0200.0000.0%$0.020$0.020$0.020327,200
$0.0200.0000.0%$0.020$0.030$0.020551,400
$0.0200.0000.0%$0.020$0.020$0.020107,700
$0.0200.0000.0%$0.030$0.030$0.020274,700
$0.0200.0000.0%$0.020$0.020$0.0201,380,100
$0.0200.0000.0%$0.020$0.020$0.020271,700
$0.020-0.010-33.3%$0.020$0.030$0.020428,300
$0.0300.0000.0%$0.020$0.030$0.020328,200
$0.0300.0000.0%$0.030$0.030$0.030299,900
$0.030+0.010+50.0%$0.030$0.030$0.020629,000
$0.0200.0000.0%$0.030$0.030$0.020365,700
$0.020-0.010-33.3%$0.030$0.030$0.020827,400
$0.030+0.010+50.0%$0.020$0.030$0.020843,900
$0.020-0.010-33.3%$0.030$0.030$0.020163,300
$0.0300.0000.0%$0.030$0.030$0.030221,800
$0.0300.0000.0%$0.030$0.030$0.030403,600
$0.0300.0000.0%$0.030$0.030$0.030195,400
$0.0300.0000.0%$0.030$0.030$0.030675,500
$0.0300.0000.0%$0.030$0.030$0.03031,400
$0.0300.0000.0%$0.030$0.030$0.030268,000
$0.0300.0000.0%$0.030$0.030$0.03090,000
$0.0300.0000.0%$0.030$0.030$0.030326,000
$0.0300.0000.0%$0.030$0.040$0.030126,700
$0.030-0.010-25.0%$0.030$0.030$0.03010,500
$0.040+0.010+33.3%$0.030$0.040$0.030233,300
$0.0300.0000.0%$0.030$0.030$0.030156,300
$0.0300.0000.0%$0.030$0.030$0.03087,100
$0.0300.0000.0%$0.030$0.030$0.03075,800
$0.0300.0000.0%$0.030$0.030$0.030248,400
$0.0300.0000.0%$0.040$0.040$0.0301,180,700
$0.030-0.010-25.0%$0.040$0.040$0.030163,400
$0.0400.0000.0%$0.040$0.040$0.030433,100
$0.0400.0000.0%$0.040$0.040$0.040138,900
$0.0400.0000.0%$0.040$0.040$0.04099,600

Splits

2 splits since 2011 · OTC:OTLC · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
1-for-20Consolidation
Ticker
OTC:OTLC
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Oncotelic Therapeutics Inc news

Oncotelic Therapeutics Inc on 6ix

Sector
Health care
Industry
Biotechnology
News releases
3 in the last 12 months · 3 in all · newest Oct 26, 2026 · oldest 2026
Decks
32 decks · latest Oct 26, 2026

Valuation

P/E 0.0× against a median of 2.6×: the lowest of 2 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$5.52M USD
P/E
0.0×
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.07

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Oncotelic Therapeutics Inc · OTC:OTLCUS$5.58MUS$5.52M0.0×n/an/a0.0×n/a0.0×0.07
Addex Therapeutics Ltd · SIX:ADXNUS$5.96MUS$5.13Mn/a68.2×n/a2.6×n/a0.0×n/a
Argenica Therapeutics Ltd · ASX:AGNUS$5.95MUS$1.74Mn/an/an/a1.5×n/a0.0×n/a
Marvel Biosciences Corp · TSXV:MRVLUS$5.91MUS$6.04Mn/an/an/an/an/an/a0.91
Exicure, Inc. · NASDAQ:XCURUS$5.89MUS$4.67Mn/an/an/a3.1×n/a0.0×0.49
Tempest Therapeutics, Inc. · NASDAQ:TPSTUS$5.74MUS$4.84Mn/an/an/an/an/an/a1.09
Theriva Biologics, Inc. · AMEX:TOVXUS$5.51MUS$461,120n/an/an/a0.5×n/a0.3×2.65
Hemostemix Inc · TSXV:HEMUS$5.35MUS$7.69Mn/an/an/an/an/an/a0.47
Curative Biotechnology Inc · OTC:CUBTUS$5.34MUS$6.55Mn/an/an/an/an/an/a1.27
Abpro Holdings, Inc. · OTC:ABPOUS$5.31MUS$1.07M2.6×n/an/an/an/an/a-0.79
CNS Pharmaceuticals, Inc. · NASDAQ:CNSPUS$5.25M−US$11.96Mn/an/an/a0.3×n/a0.0×0.74
Median of the othersUS$5.62MUS$4.75M2.6×68.2×1.5×0.0×0.83

Team and board

OfficerRole
Vuong TrieuCEO/Chairman of Oncotelic Inc.
Amit ShahCFO
Anthony E. MaidaChief Clinical Officer-Translational Medicine

Events

QuarterResultsShare move
Q2 2026Aug 24, 2026−25.0%
Q1 2026Apr 20, 20260.0%
Q3 2025Nov 28, 20250.0%
Q2 2025Aug 29, 20250.0%
Q1 2025May 12, 2025 · After close0.0%
Q4 2024Feb 26, 20250.0%
Q3 2024Nov 12, 2024 · Before open0.0%
Q2 2024Aug 14, 2024 · After close0.0%
Q1 2024Apr 12, 2024 · After close0.0%
Q3 2023Nov 14, 2023 · Before open−25.0%
All 20 quarters
QuarterResultsShare move
Q2 2023Aug 18, 2023 · After close0.0%
Q1 2023Apr 14, 2023 · After close0.0%
Q4 2022Mar 1, 20230.0%
Q3 2022Nov 18, 2022 · After close0.0%
Q2 2022Aug 22, 2022 · Before open−11.1%
Q1 2022Apr 15, 2022 · After close0.0%
Q4 2021Mar 2, 2022+4.2%
Quarter to Sep 30, 2021Nov 22, 2021 · After close0.0%
Quarter to Jun 30, 2021Aug 20, 2021 · After close0.0%
Quarter to Mar 31, 2021May 24, 2021 · After close−3.3%

Open Events

Decks

DeckKindSlidesDate
22nd Drug Discovery Strategic Summit (October 2026)Conference16 slidesOct 26, 2026
Drug Discovery-2026Conference13 slidesOct 13, 2026
Drug Discovery 2026Conference13 slidesOct 13, 2026
Investor Presentation (July 2026)Investor deck5 slidesJul 14, 2026
Investor Presentation (October 2025)Investor deck37 slidesOct 22, 2025
5th Symposium on World Cancer Research (SWCR 2025)Conference36 slidesMar 24, 2025
Technical Presentation (July 2022)Technical11 slidesJul 15, 2022
Investor Presentation (June 2022)Investor deck18 slidesJune 2022
MedInvest March 2022Conference22 slidesApr 1, 2022
Investor Presentation (February 2022)Investor deck13 slidesFeb 9, 2022
All 32 decks
DeckKindSlidesDate
Corporate Update (January 2022)Corporate update16 slidesJan 28, 2022
Investor Presentation (January 2022)Investor deck16 slidesJan 26, 2022
Investor Presentation (September 2021)Investor deck15 slidesSep 8, 2021
Corporate Update (August 2021)Corporate update18 slidesAug 26, 2021
Merger or Acquisition (August 2021)Merger or acquisition6 slidesAug 17, 2021
Investor Presentation (July 2021)Investor deck31 slidesJul 14, 2021
Mateon Therapeutics — Corporate Update (February 2021)Corporate update11 slidesFeb 18, 2021
Investor Presentation (December 2020)Investor deck33 slidesDec 1, 2020
Mateon Therapeutics — Pharma Forum 2020Conference21 slidesSep 22, 2020
Mateon Therapeutics — Corporate Update (June 2020)Corporate update19 slidesJun 18, 2020
Mateon Therapeutics — Corporate Update (June 2020)Corporate update14 slidesJun 12, 2020
Mateon Therapeutics — Corporate Update (April 2020)Corporate update15 slidesApr 20, 2020
Mateon Therapeutics — Investor Presentation (December 2019)Investor deck18 slidesDec 6, 2019
Mateon Therapeutics — Technical Presentation (November 2019)Technical17 slidesNov 25, 2019
Mateon Therapeutics — Investor Presentation (October 2019)Investor deck15 slidesOct 29, 2019
Mateon Therapeutics — Investor Presentation (October 2019)Investor deck30 slidesOct 9, 2019
Mateon Therapeutics — Investor Presentation (September 2019)Investor deck27 slidesSep 3, 2019
Mateon Therapeutics — Investor Presentation (June 2019)Investor deck19 slidesJun 4, 2019
Mateon Therapeutics — Investor Presentation (April 2019)Investor deck29 slidesApr 30, 2019
Mateon Therapeutics — IPO Roadshow (September 2017)IPO roadshow44 slidesSep 11, 2017
Mateon Therapeutics — IPO Roadshow (June 2017)IPO roadshow45 slidesJun 19, 2017
Mateon Therapeutics — Investor Presentation (April 2017)Investor deck42 slidesApr 24, 2017

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue70.0K1.74M
Research and development4.36K61.1K756.9K3.66M4.30M1.37M649.8K10.5M8.76M
Operating income-3.19M-3.58M-6.65M-9.72M-9.13M-7.58M-4.31M-712.7K-13.8M-13.8M
Depreciation and amortization10.1K37.4K9.24K2.00K9.00K19.0K
EBITDA-9.12M-7.55M-4.30M-710.7K-13.8M-13.7M
Interest expense1.04M2.97M2.00M2.00M749.5K
Income before tax360.6M-4.78M
Income tax111.5M
Net income249.3M-4.52M-7.90M5.09M-9.39M-9.50M-6.64M-712.7K-13.8M-13.7M
Earnings per share, basic0.590.01-0.020.01-0.03-0.11-0.11-0.12-0.52-0.51
Earnings per share, diluted0.59-0.01-0.020.01-0.03-0.11-0.11-0.12-0.52-0.51

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents88.9K86.1K170.4K241.5K568.8K474.0K82.0K2.50K1.11M3.54M
Short-term investments8.51M
Receivables51.3K19.0K19.0K19.7K19.7K19.7K149.7K
Current assets1.20M134.2K271.7K303.2K627.3K615.6K273.0K2.50K1.14M14.1M
Property, plant and equipment47.6K2.00K11.0K
Goodwill2.79M2.79M5.99M12.1M21.1M21.1M21.1M
Total assets393.1M26.7M30.0M36.1M23.6M23.7M23.7M2.75M1.17M14.1M
Accounts payable332.4K1.93M1.94M1.79M915.0K788.0K310.0K
Current liabilities18.1M19.2M16.5M16.9M15.5M11.2M6.78M283.0K1.65M1.61M
Total liabilities131.4M19.2M18.4M16.9M
Shareholders' equity262.8M8.25M12.1M19.4M7.96M11.8M16.9M2.46M-483.6K12.5M
Shares outstanding442.6M407.3M399.2M391.8M375.3M90.6M84.1M6.84M26.5M26.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-1.38M-740.3K-1.32M-1.45M-4.43M-2.81M-2.28M-241.0K-10.9M-15.2M
Cash from investing189.3K8.51M-8.51M
Cash from financing1.39M656.0K1.25M1.13M4.53M3.22M2.17M240.0K
Change in cash2.73K-84.3K-71.0K-327.3K94.8K412.1K79.5K-980-2.42M-23.8M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
8-K · Current reportOct 26, 2026Current reportSEC
8-K · Current reportOct 13, 2026Current reportSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026Material contractSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
DJul 22, 2026Other filingsSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
8-K · Current reportJul 14, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJul 14, 2026Management or board changeSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
8-K · Current reportJun 29, 2026Material contractSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026Acquisition or disposalSEC
8-K · Current reportApr 16, 2026Current reportSEC
10-K · Annual reportApr 15, 2026Annual reportSEC
8-K · Current reportApr 2, 2026Material contractSEC
NT 10-K · Late filing noticeMar 31, 2026Explanation requestSEC
8-K · Current reportMar 30, 2026Current reportSEC
8-K · Current reportMar 27, 2026Current reportSEC
8-K · Current reportJan 29, 2026Material contractSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
8-K · Current reportJan 26, 2026Material contractSEC
8-K · Current reportJan 7, 2026Material contractSEC
8-K · Current reportJan 6, 2026Material contractSEC
8-K · Current reportJan 6, 2026Material contractSEC
8-K · Current reportDec 30, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveDec 29, 2025Other filingsSEC
424B3 · ProspectusDec 23, 2025Offer documentSEC
8-K · Current reportDec 23, 2025Current reportSEC
CORRESP · Letter to the SECDec 22, 2025Other filingsSEC
S-1/A · Registration statement, amendedDec 22, 2025Offer documentSEC
DDec 11, 2025Other filingsSEC
8-K · Current reportDec 9, 2025Material contractSEC
S-1 · Registration statementNov 21, 2025Offer documentSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
10-Q · Quarterly reportNov 17, 2025Quarterly reportSEC
NT 10-Q · Late filing noticeNov 14, 2025Explanation requestSEC
8-K · Current reportOct 22, 2025Current reportSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025Material contractSEC
8-K · Current reportAug 6, 2025Material contractSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
424B3 · ProspectusApr 29, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 22, 2025Other filingsSEC
POS AM · Amendment to an effective registrationApr 15, 2025Offer documentSEC
10-K · Annual reportApr 15, 2025Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2025Explanation requestSEC
8-K · Current reportMar 25, 2025Current reportSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
8-K · Current reportJan 2, 2025Current reportSEC
4 · Change in ownershipNov 26, 2024Insider tradeSEC
10-Q · Quarterly reportNov 19, 2024Quarterly reportSEC
NT 10-Q · Late filing noticeNov 14, 2024Explanation requestSEC
4 · Change in ownershipAug 27, 2024Insider tradeSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportApr 29, 2024Current reportSEC
424B3 · ProspectusApr 26, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 23, 2024Other filingsSEC
POS AM · Amendment to an effective registrationApr 18, 2024Offer documentSEC
POS AM · Amendment to an effective registrationApr 12, 2024Offer documentSEC
10-K · Annual reportApr 12, 2024Annual reportSEC
NT 10-K · Late filing noticeApr 1, 2024Explanation requestSEC
8-K · Current reportFeb 2, 2024Material contractSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportOct 30, 2023Material contractSEC
8-K · Current reportAug 23, 2023Current reportSEC
10-Q · Quarterly reportAug 18, 2023Quarterly reportSEC
NT 10-Q · Late filing noticeAug 14, 2023Explanation requestSEC
DJul 13, 2023Other filingsSEC
8-K · Current reportJul 13, 2023Material contractSEC
4 · Change in ownershipJun 30, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 16, 2023Insider tradeSEC
4 · Change in ownershipMay 31, 2023Insider tradeSEC
10-Q · Quarterly reportMay 19, 2023Quarterly reportSEC
8-K · Current reportMay 19, 2023Current reportSEC
NT 10-Q · Late filing noticeMay 15, 2023Explanation requestSEC
424B3 · ProspectusMay 2, 2023Offer documentSEC
4 · Change in ownershipMay 2, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 26, 2023Other filingsSEC
POS AM · Amendment to an effective registrationApr 19, 2023Offer documentSEC
10-K/A · Annual report, amendedApr 19, 2023Annual reportSEC
POS AM · Amendment to an effective registrationApr 14, 2023Offer documentSEC
10-K · Annual reportApr 14, 2023Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2023Explanation requestSEC
8-K · Current reportMar 13, 2023Current reportSEC
8-K · Current reportMar 2, 2023Management or board changeSEC
8-K · Current reportJan 3, 2023Current reportSEC
8-K · Current reportDec 20, 2022Current reportSEC
4 · Change in ownershipDec 7, 2022Insider tradeSEC
4 · Change in ownershipNov 25, 2022Insider tradeSEC
10-Q · Quarterly reportNov 18, 2022Quarterly reportSEC
NT 10-Q · Late filing noticeNov 14, 2022Explanation requestSEC
4 · Change in ownershipSep 28, 2022Insider tradeSEC
4 · Change in ownershipAug 29, 2022Insider tradeSEC
10-Q · Quarterly reportAug 22, 2022Quarterly reportSEC
NT 10-Q · Late filing noticeAug 15, 2022Explanation requestSEC
8-K · Current reportJul 15, 2022Current reportSEC
8-K · Current reportJun 27, 2022Material contractSEC
8-K · Current reportJun 22, 2022Current reportSEC
8-K · Current reportJun 3, 2022Material contractSEC
10-Q · Quarterly reportMay 23, 2022Quarterly reportSEC
NT 10-Q · Late filing noticeMay 16, 2022Explanation requestSEC
424B3 · ProspectusMay 11, 2022Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 9, 2022Other filingsSEC
8-K · Current reportMay 6, 2022Management or board changeSEC
POS AM · Amendment to an effective registrationApr 26, 2022Offer documentSEC
10-K · Annual reportApr 15, 2022Annual reportSEC
8-K · Current reportApr 13, 2022Current reportSEC
8-K · Current reportApr 6, 2022Material contractSEC
8-K · Current reportApr 4, 2022Material contractSEC
8-K · Current reportApr 1, 2022Current reportSEC
NT 10-K · Late filing noticeMar 31, 2022Explanation requestSEC
8-K · Current reportFeb 17, 2022Current reportSEC
8-K · Current reportFeb 15, 2022Material contractSEC
8-K · Current reportFeb 9, 2022Current reportSEC
8-K · Current reportFeb 2, 2022Material contractSEC
8-K · Current reportJan 28, 2022Current reportSEC
8-K · Current reportDec 23, 2021Current reportSEC
8-K · Current reportDec 15, 2021Material contractSEC
8-K · Current reportDec 1, 2021Material contractSEC
8-K · Current reportNov 24, 2021Current reportSEC
8-K · Current reportNov 23, 2021ResultsSEC
10-Q · Quarterly reportNov 22, 2021Quarterly reportSEC
8-K · Current reportNov 16, 2021Current reportSEC
NT 10-Q · Late filing noticeNov 15, 2021Explanation requestSEC
8-K · Current reportOct 28, 2021Material contractSEC
8-K · Current reportOct 4, 2021Material contractSEC
8-K · Current reportSep 27, 2021Material contractSEC
424B3 · ProspectusSep 24, 2021Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 10, 2021Other filingsSEC
4 · Change in ownershipSep 8, 2021Insider tradeSEC
4 · Change in ownershipSep 8, 2021Insider tradeSEC
4 · Change in ownershipSep 8, 2021Insider tradeSEC
4 · Change in ownershipSep 8, 2021Insider tradeSEC
8-K · Current reportSep 8, 2021Current reportSEC
S-3/A · Registration statement, amendedSep 7, 2021Offer documentSEC
8-K · Current reportSep 3, 2021Material contractSEC
8-K · Current reportAug 26, 2021Current reportSEC
S-3 · Registration statementAug 20, 2021Offer documentSEC
10-Q · Quarterly reportAug 20, 2021Quarterly reportSEC
8-K · Current reportAug 17, 2021Current reportSEC
NT 10-Q · Late filing noticeAug 16, 2021Explanation requestSEC
8-K · Current reportAug 5, 2021Material contractSEC
8-K · Current reportJul 19, 2021Management or board changeSEC
4 · Change in ownershipJul 16, 2021Insider tradeSEC
4 · Change in ownershipJul 16, 2021Insider tradeSEC
4 · Change in ownershipJul 16, 2021Insider tradeSEC
4 · Change in ownershipJul 16, 2021Insider tradeSEC
4 · Change in ownershipJul 16, 2021Insider tradeSEC
4 · Change in ownershipJul 16, 2021Insider tradeSEC
8-K · Current reportJul 2, 2021Material contractSEC
8-K · Current reportJun 15, 2021Current reportSEC
424B3 · ProspectusJun 3, 2021Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 3, 2021Other filingsSEC
8-K · Current reportJun 1, 2021Material contractSEC
CORRESP · Letter to the SECMay 28, 2021Other filingsSEC
UPLOAD · Letter from the SECMay 27, 2021Other filingsSEC
S-1 · Registration statementMay 24, 2021Offer documentSEC
10-Q · Quarterly reportMay 24, 2021Quarterly reportSEC
NT 10-Q · Late filing noticeMay 17, 2021Explanation requestSEC
8-K · Current reportMay 7, 2021Material contractSEC
8-K · Current reportApr 21, 2021Current reportSEC
S-8 · Registration statement for employee plansApr 16, 2021Offer documentSEC
10-K · Annual reportApr 15, 2021Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2021Explanation requestSEC
8-K · Current reportMar 30, 2021Current reportSEC
8-K · Current reportMar 26, 2021Material contractSEC
8-K · Current reportMar 2, 2021Current reportSEC
8-K · Current reportFeb 18, 2021Current reportSEC
8-K · Current reportFeb 2, 2021Current reportSEC
8-K · Current reportFeb 2, 2021Current reportSEC
8-K · Current reportFeb 2, 2021Current reportSEC
8-K · Current reportFeb 1, 2021Current reportSEC
8-K · Current reportJan 15, 2021Current reportSEC
8-K · Current reportDec 15, 2020Current reportSEC
8-K · Current reportDec 3, 2020Current reportSEC
4 · Change in ownershipNov 24, 2020Insider tradeSEC
4 · Change in ownershipNov 23, 2020Insider tradeSEC
4 · Change in ownershipNov 23, 2020Insider tradeSEC
10-Q · Quarterly reportNov 16, 2020Quarterly reportSEC
8-K · Current reportNov 4, 2020Current reportSEC
8-K · Current reportOct 21, 2020Current reportSEC
8-K · Current reportSep 30, 2020Current reportSEC
8-K · Current reportSep 28, 2020Current reportSEC
8-K · Current reportSep 21, 2020Current reportSEC
8-K · Current reportAug 24, 2020Current reportSEC
8-K · Current reportAug 19, 2020Current reportSEC
8-K · Current reportAug 13, 2020Meeting outcomeSEC

This page holds 200 of 1,008 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Oncotelic Therapeutics Inc’s releases · as of Nov 13, 2026

Common shares
457,512,796
Fully diluted
457,512,796

Fully diluted

LineSharesAs of
Common shares457,512,796Nov 13, 2026

Share count over time

CountShares
Nov 13, 2026457,512,796

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Trieu Vuong
Director, Officer: CHAIRMAN AND CEO, 10% owner
Buy1,044,990USD 0.02US$17,765Oct 29, 2026
Trieu Vuong
Director, Officer: CHAIRMAN AND CEO, 10% owner
Buy312,000USD 0.02US$5,772Oct 28, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Frederick W. Driscoll
Other companies: Lite Strategy, Inc. (Chairperson, Non-Executive Director · Since at least Feb 22, 2018); Cellectar Biosciences, Inc. (Director · Since at least Apr 10, 2017); Invivyd, Inc. (Interim CFO · Oct 13, 2022 – Oct 13, 2022 · Past); ConforMIS Inc (INTERIM CFO & INTERIM TREAS · Oct 23, 2019 – Oct 23, 2019 · Past); Cue Biopharma, Inc. (Director · Jun 26, 2018 – Jan 2, 2025 · Past); ImmunityBio, Inc. (Director · Sep 18, 2017 – Aug 11, 2020 · Past); Flexion Therapeutics Inc (Chief Financial Officer · Feb 11, 2014 – Nov 19, 2021 · Past); Novavax, Inc. (VP, CFO & Treasurer · Aug 24, 2009 – Mar 2, 2013 · Past); Genelabs Technologies Inc (CEO/PRESIDENT · Nov 1, 2007 – Jan 7, 2009 · Past)
Director · Jan 1, 2014 – Jun 1, 2016 · Past
Arthur Laffer
Other companies: Brera Holdings PLC (Director · Since at least Mar 18, 2026); NexPoint Diversified Real Estate Trust (Trustee · Since at least Jul 1, 2022); NexPoint Real Estate Finance, Inc. (Director · Since at least Feb 6, 2020); NexPoint Residential Trust, Inc. (Director · Since at least May 8, 2015); VerifyMe, Inc. (Director · Mar 23, 2019 – Mar 10, 2025 · Past); GEE Group Inc. (Director · Jan 12, 2015 – Jun 15, 2018 · Past); CLARCOR Inc (Director · Jul 10, 2007 – Jul 10, 2007 · Past)
Director · Mar 3, 2006 – Dec 31, 2009 · Past
Mark Kessel
Other companies: VivoSim Labs, Inc. (Director · Aug 17, 2016 – Sep 5, 2019 · Past); Dynavax Technologies Corporation (Director · Dec 30, 2009 – Oct 16, 2012 · Past); Agenus Inc. (Director · Jan 13, 2006 – Oct 2, 2006 · Past)
Director · Oct 22, 2008 – Oct 31, 2011 · Past
Anthony E Maida III
Other companies: Range Impact Inc (Director · Mar 16, 2012 – May 8, 2019 · Past); Spectrum Pharmaceuticals Inc (Director · Feb 20, 2007 – May 29, 2019 · Past)
DIRECTOR AND CMO - TRANS. MED., Director · Since at least May 11, 2020
Bobby W Phd Sandage
Other companies: Fortress Biotech, Inc. (President, Director · Sep 13, 2011 – Apr 5, 2013 · Past); Indevus Pharmaceuticals Inc (Executive Vice President · Jan 25, 2006 – Feb 23, 2009 · Past)
Director · Oct 25, 2016 – Jun 20, 2018 · Past
Gerald PhD McMahon
Other companies: Harpoon Therapeutics Inc (President and CEO, Director · Feb 7, 2019 – Jan 28, 2021 · Past); Celldex Therapeutics, Inc. (Director · Dec 14, 2016 – Dec 3, 2018 · Past)
Director · Sep 2, 2011 – Jun 1, 2016 · Past
John A Kollins
Other companies: Satsuma Pharmaceuticals Inc (President and CEO, Director · Sep 12, 2019 – Jun 6, 2023 · Past); Paratek Pharmaceuticals Inc (SVP, Chief Business Officer · Jun 1, 2012 – Oct 30, 2014 · Past)
Chief Executive Officer, Director · Mar 5, 2007 – Jan 20, 2009 · Past
Steven W. King
Other companies: Mosaic ImmunoEngineering Inc (President and CEO, Director · Aug 21, 2020 – Feb 18, 2022 · Past); Avid Bioservices Inc (President & CEO, Director · Feb 15, 2006 – Oct 31, 2017 · Past)
Director · Since at least May 11, 2020
David Diamond
Other companies: RenovoRx, Inc. (Director · Aug 25, 2021 – Oct 1, 2023 · Past)
Director · Jan 22, 2020 – Jul 8, 2021 · Past
Harri V Taranto
Other companies: Dynavax Technologies Corporation (Director · Dec 30, 2009 – Apr 16, 2010 · Past)
Director · Oct 1, 2008 – Jul 20, 2009 · Past
All 24 people
PersonSeat
Vuong Trieu
Other companies: Sorrento Therapeutics, Inc. (CSO, Director · Sep 9, 2013 – Oct 29, 2013 · Past)
CEO/Chairman of Oncotelic Inc. · Since at least Apr 22, 2019
Amit ShahCFO · Since at least Nov 20, 2020
Anthony E. MaidaChief Clinical Officer-Translational Medicine · Since at least Nov 5, 2026
Chulho ParkCHIEF TECHNOLOGY OFFICER · Apr 22, 2019 – Nov 19, 2020 · Past
Donald Rogers ReynoldsDirector · Oct 25, 2016 – Jun 20, 2018 · Past
Fatih UckunChief Medical Officer · Apr 22, 2019 – Apr 22, 2019 · Past
Matthew M LoarChief Financial Officer · Jul 20, 2015 – Jun 20, 2018 · Past
Pamela HaController · Jun 4, 2015 – Jun 4, 2015 · Past
Patricia A WalickeVP and Chief Medical Officer · Jul 27, 2007 – Jan 20, 2009 · Past
Per Olof SoderbergDirector · Mar 15, 2006 – Dec 15, 2006 · Past
Peter HarrisChief Medical Officer · Jun 14, 2006 – Jan 25, 2007 · Past
Saran SaundCBO · Since at least Mar 31, 2021
Seymour Howard FeinCRO/CMO · Since at least Jul 10, 2026
William D SchwietermanPresident and CEO, Director · Mar 21, 2016 – Jun 20, 2018 · Past

Open People

Log in to ask 6ix AI your own questions about Oncotelic Therapeutics Inc.